<p>Here Ni-catalysed multicomponent reductive cross-coupling of thiourea dioxide, aziridines and alkyl halides is disclosed, enabling the divergent synthesis of β-amino sulfides and disulfides. The β-amino sulfides are selectively synthesized using a planar bidentate 2,9-dimethyl-1,10-phenanthroline ligand through a Ni<sup>I</sup>/Ni<sup>III</sup> catalytic cycle. Moreover, the non-planar bidentate ligand 6,6′-dimethyl-2,2′-dipyridyl, possessing an axial torsional dihedral angle, affords β-amino disulfides via a Ni<sup>0</sup>/Ni<sup>II</sup>/Ni<sup>I</sup> catalytic cycle. Density functional theory calculations demonstrate that the planar bidentate ligand converts the catalytic centre from Ni<sup>I</sup>–SR to a Ni<sup>III</sup> species via oxidative addition with a monosulfurating transformation, and the non-planar bidentate ligand induces the dimerization of Ni<sup>I</sup>–SR, forming a sulfido-bridged dimer for disulfurating transformations. Clinically applied pharmaceuticals, such as bezafibrate, indometacin and thalidomide, with reactive functional groups, are compatible with the versatile sulfuration linkage, demonstrating the applicability of this strategy.</p><p></p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Ligand-controlled divergent sulfuration and disulfuration via Ni-catalysed reductive cross-coupling involving thiourea dioxide

  • Su Huang,
  • Daming Zeng,
  • Ming Wang,
  • Xuefeng Jiang

摘要

Here Ni-catalysed multicomponent reductive cross-coupling of thiourea dioxide, aziridines and alkyl halides is disclosed, enabling the divergent synthesis of β-amino sulfides and disulfides. The β-amino sulfides are selectively synthesized using a planar bidentate 2,9-dimethyl-1,10-phenanthroline ligand through a NiI/NiIII catalytic cycle. Moreover, the non-planar bidentate ligand 6,6′-dimethyl-2,2′-dipyridyl, possessing an axial torsional dihedral angle, affords β-amino disulfides via a Ni0/NiII/NiI catalytic cycle. Density functional theory calculations demonstrate that the planar bidentate ligand converts the catalytic centre from NiI–SR to a NiIII species via oxidative addition with a monosulfurating transformation, and the non-planar bidentate ligand induces the dimerization of NiI–SR, forming a sulfido-bridged dimer for disulfurating transformations. Clinically applied pharmaceuticals, such as bezafibrate, indometacin and thalidomide, with reactive functional groups, are compatible with the versatile sulfuration linkage, demonstrating the applicability of this strategy.